Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study

Cited by

This article is cited by 3 publications

1. Biener, L., Pizarro, C., & Skowasch, D. (2024). Chronisch-obstruktive Lungenerkrankung (COPD) – Eosinophilie und neue Arzneimitteltherapien [Chronic obstructive pulmonary disease (COPD): eosinophilia and novel drug therapies]. Innere Medizin (Heidelberg, Germany), 10.1007/s00108-024-01725-z. Advance online publication. https://doi.org/10.1007/s00108-024-01725-z
2. Müllerová, H., Chan, J. S. K., Heatley, H., Carter, V., Townend, J., Skinner, D., Franzén, S., Marshall, J., & Price, D. (2024). Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success. International journal of chronic obstructive pulmonary disease, 19, 1153–1166. https://doi.org/10.2147/COPD.S452624
3. Singh, D., Han, M. K., Hawkins, N. M., Hurst, J. R., Kocks, J. W. H., Skolnik, N., Stolz, D., El Khoury, J., & Gale, C. P. (2024). Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Advances in therapy, 10.1007/s12325-024-02855-4. Advance online publication. https://doi.org/10.1007/s12325-024-02855-4